TABATA Tsutomu
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Professor and Division head
Article types Original article
Language English
Peer review Peer reviewed
Title Proposal of a Two-Tier System in Grouping Adenocarcinoma of the Uterine Cervix.
Journal Formal name：Cancers
Abbreviation：Cancers (Basel)
ISSN code：20726694/20726694
Domestic / ForeginForegin
Volume, Issue, Page 12(5),pp.1251
Author and coauthor Machida Hiroko, Matsuo Koji, Matsuzaki Shinya, Yamagami Wataru, Ebina Yasuhiko, Kobayashi Yoichi, Tabata Tsutomu, Kaneuchi Masanori, Nagase Satoru, Enomoto Takayuki, Mikami Mikio
Publication date 2020/05
Summary (1) Background: This study examined the use of a two-tier system in grouping cervical adenocarcinoma for survival discrimination. (2) Methods: A nationwide retrospective observational cohort study was conducted using the Japan Society of Gynecologic Oncology tumor registry database from 2001 to 2015 (n = 86,754). Adenocarcinoma subtypes were grouped as type 1 (endocervical usual type and endometrioid) or type 2 (serous, clear, mucinous, and not otherwise specified), based on their relative survival compared with that of squamous tumors. (3) Results: The majority of the adenocarcinoma cases were type 1 (n = 10,121) versus type 2 tumors (n = 5157). Type 2 tumors were more likely to be old and have stage IV disease than those with squamous tumors. The number of type 2 tumors increased from 2001 to 2014 (106.1% relative increase, p < 0.001). Type 2 tumors had disproportionally poorer survival compared to other types (5-year survival rates: 68.9% for type 2, 75.4% for type 1, and 78.0% for squamous; p < 0.001). On multivariate analysis, type 2 tumors remained an independent prognostic factor associated with decreased survival compared with squamous (adjusted hazard ratio 2.00, 95% CI 1.84-2.15, p < 0.001). (4) Conclusion: The survival of cervical adenocarcinoma varies largely across the histological subtypes, and the proposed two-tier grouping may be useful for survival discrimination.
DOI 10.3390/cancers12051251
PMID 32429283